Index - P/E - EPS (ttm) -1.45 Insider Own 0.20% Shs Outstand 66.87M Perf Week 5.52%
Market Cap 614.86M Forward P/E - EPS next Y -1.86 Insider Trans -53.88% Shs Float 60.26M Perf Month -2.33%
Income -96.30M PEG - EPS next Q -0.45 Inst Own 96.50% Short Float / Ratio 7.71% / 4.65 Perf Quarter -31.22%
Sales 30.80M P/S 19.96 EPS this Y 16.80% Inst Trans 0.41% Short Interest 4.65M Perf Half Y -42.25%
Book/sh 2.64 P/B 3.33 EPS next Y -6.90% ROA -37.40% Target Price 29.12 Perf Year -34.30%
Cash/sh 2.44 P/C 3.60 EPS next 5Y - ROE -46.40% 52W Range 5.77 - 18.96 Perf YTD -44.19%
Dividend - P/FCF - EPS past 5Y 11.80% ROI -45.50% 52W High -53.64% Beta 0.53
Dividend % - Quick Ratio 10.10 Sales past 5Y 77.60% Gross Margin 58.90% 52W Low 52.34% ATR 0.45
Employees 105 Current Ratio 10.10 Sales Q/Q 66.70% Oper. Margin - RSI (14) 55.43 Volatility 5.52% 5.18%
Optionable Yes Debt/Eq 0.00 EPS Q/Q -37.70% Profit Margin - Rel Volume 1.31 Prev Close 8.70
Shortable Yes LT Debt/Eq 0.00 Earnings May 08 BMO Payout - Avg Volume 999.37K Price 8.79
Recom 1.40 SMA20 5.24% SMA50 2.24% SMA200 -34.48% Volume 1,309,197 Change 1.03%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-14-22 Initiated Stifel
Buy
$29
Dec-01-22 Initiated Goldman
Buy
$25
Oct-06-22 Initiated BTIG Research
Buy
$32
Jul-23-21 Resumed Jefferies
Buy
$27 → $32
Jun-15-21 Initiated Piper Sandler
Overweight
$30
Apr-21-21 Initiated H.C. Wainwright
Buy
$40
Oct-22-19 Upgrade SVB Leerink
Mkt Perform → Outperform
Sep-06-19 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Jun-27-19 Downgrade SVB Leerink
Outperform → Mkt Perform
May-06-19 Initiated SVB Leerink
Outperform
$13
Mar-28-18 Resumed Leerink Partners
Outperform
$52
Feb-09-18 Initiated Guggenheim
Buy
$53
Jun-16-17 Initiated Cantor Fitzgerald
Overweight
$50
Nov-29-16 Initiated Leerink Partners
Outperform
$54
Sep-30-16 Initiated JMP Securities
Mkt Outperform
Jun-10-16 Initiated Guggenheim
Buy
$35
Nov-02-15 Initiated Jefferies
Buy
$20
Nov-02-15 Initiated Citigroup
Buy
Show Previous Ratings
Jun-02-23 07:00AM May-18-23 01:50PM May-10-23 06:04AM May-08-23 11:55PM (Thomson Reuters StreetEvents) -6.46%
08:15AM
07:08AM
Loading…
07:08AM 07:00AM May-05-23 06:49AM May-02-23 07:01AM Apr-27-23 04:35AM Apr-24-23 02:37PM Apr-04-23 07:40AM Mar-27-23 07:00AM Mar-10-23 11:34AM (American City Business Journals)
Mar-06-23 03:59PM
02:32PM
Loading…
02:32PM 01:03PM 11:50AM 07:00AM Feb-23-23 08:35AM 07:00AM Feb-22-23 06:01AM Feb-09-23 04:01PM Jan-06-23 07:01AM Nov-29-22 07:00AM Nov-26-22 01:39PM (American City Business Journals)
Nov-22-22 04:01PM Nov-16-22 12:10PM Nov-10-22 04:01PM Nov-08-22 08:25AM
07:00AM
Loading…
07:00AM Oct-26-22 06:44AM Sep-27-22 07:00AM Sep-15-22 06:46AM Aug-30-22 07:00AM Aug-25-22 07:00AM Aug-05-22 07:59AM Aug-03-22 08:25AM 07:00AM Aug-01-22 07:00AM Jul-15-22 12:00PM Jul-08-22 09:40AM Jul-01-22 09:36AM (American City Business Journals)
Jun-27-22 07:00AM Jun-22-22 09:40AM Jun-20-22 08:20AM Jun-13-22 09:55AM Jun-06-22 09:40AM Jun-01-22 04:01PM May-27-22 09:55AM May-17-22 11:53AM May-16-22 07:00AM May-10-22 08:15AM 07:00AM May-04-22 07:35PM May-03-22 07:00AM May-02-22 06:10AM Apr-13-22 12:17AM Feb-24-22 08:55AM 07:00AM Feb-21-22 04:34AM Feb-17-22 03:03PM Feb-06-22 04:33PM Feb-02-22 07:00AM Feb-01-22 04:01PM Jan-11-22 04:01PM Dec-27-21 07:00AM Dec-20-21 05:21PM Dec-08-21 11:59AM Dec-03-21 07:00AM Nov-23-21 04:13AM Nov-18-21 04:01PM Nov-03-21 07:00AM Nov-02-21 08:25AM 07:00AM Oct-27-21 03:03PM Oct-12-21 07:16PM Sep-29-21 08:47AM Sep-20-21 08:00AM Aug-26-21 04:01PM Aug-25-21 06:16AM Aug-05-21 10:58AM 07:00AM Jul-30-21 03:00PM Jul-08-21 07:00AM Jul-06-21 11:49AM 10:13AM Jun-09-21 07:55PM 11:00AM Jun-08-21 04:15PM 07:46AM 07:00AM May-18-21 01:25AM May-17-21 07:00AM May-07-21 08:35AM 07:00AM Apr-29-21 05:02PM Apr-26-21 01:39AM Mar-15-21 07:00AM Feb-25-21 07:00AM
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Manion Douglas J. Pres and CEO Mar 17 Buy 7.86 6,300 49,532 12,800 Mar 17 05:03 PM Manion Douglas J. Pres and CEO Mar 09 Buy 7.74 6,500 50,278 6,500 Mar 09 05:56 PM Walker Neal Director Mar 03 Sale 12.63 30,240 382,070 1,273,202 Mar 03 08:37 PM Monahan Joseph Chief Scientific Officer Mar 03 Sale 12.63 16,037 202,615 147,724 Mar 03 08:12 PM Balthaser Kevin Chief Financial Officer Mar 03 Sale 12.63 894 11,290 5,256 Mar 03 08:09 PM Walker Neal Director Mar 02 Sale 12.37 29,000 358,588 1,285,188 Mar 03 08:37 PM Monahan Joseph Chief Scientific Officer Mar 02 Sale 12.37 14,800 183,024 151,261 Mar 03 08:12 PM Balthaser Kevin Chief Financial Officer Mar 02 Sale 12.29 1,000 12,289 4,650 Mar 03 08:09 PM Monahan Joseph Chief Scientific Officer Feb 15 Sale 13.06 5,000 65,310 91,386 Feb 17 04:34 PM Loerop James Chief Business Officer Feb 08 Sale 13.89 4,267 59,272 6,983 Feb 10 04:55 PM Walker Neal Director Feb 02 Sale 16.25 5,000 81,248 1,175,763 Feb 03 05:09 PM Walker Neal Director Feb 01 Sale 16.75 25,000 418,675 1,180,763 Feb 03 05:09 PM Walker Neal Director Jan 04 Sale 14.89 15,000 223,342 1,205,763 Jan 04 06:20 PM Walker Neal Director Jan 03 Sale 15.25 25,000 381,213 1,220,763 Jan 04 06:20 PM Monahan Joseph Chief Scientific Officer Dec 15 Sale 15.88 5,000 79,412 96,386 Dec 16 04:57 PM SCHIFF ANDREW N Director Nov 14 Sale 17.08 1,371 23,417 434,455 Nov 14 04:51 PM SCHIFF ANDREW N Director Nov 11 Sale 17.06 41,160 702,177 435,826 Nov 14 04:51 PM SCHIFF ANDREW N Director Nov 10 Sale 17.02 11,395 193,995 476,986 Nov 14 04:51 PM SCHIFF ANDREW N Director Oct 26 Sale 17.00 14,540 247,253 488,381 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 25 Sale 17.02 12,018 204,516 502,921 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 24 Sale 17.01 14,616 248,586 514,939 Oct 26 07:09 PM SCHIFF ANDREW N Director Oct 18 Sale 16.89 32,093 542,022 529,555 Oct 19 04:49 PM SCHIFF ANDREW N Director Oct 17 Sale 16.05 19,944 320,087 561,648 Oct 19 04:49 PM Monahan Joseph Chief Scientific Officer Oct 17 Sale 15.98 5,000 79,908 101,386 Oct 19 04:45 PM SCHIFF ANDREW N Director Oct 07 Sale 16.16 7,324 118,349 581,592 Oct 11 04:35 PM SCHIFF ANDREW N Director Oct 06 Sale 16.54 37,839 625,744 588,916 Oct 06 05:58 PM SCHIFF ANDREW N Director Oct 04 Sale 16.01 7,700 123,259 626,755 Oct 06 05:58 PM SCHIFF ANDREW N Director Jun 17 Sale 15.14 19,565 296,269 0 Jun 21 04:57 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
